HOME >> BIOLOGY >> NEWS
The new form of trypanosomiasis discovered in India stems from a deficiency in apolipoproteinL-1

The two known types of human trypanosomiasis, endemic in two regions of the world, are sleeping sickness in Africa, caused by the parasites Trypanosoma brucei gambiense or T. b. rhodiense, and Chagas' disease in South America induced by T. cruzi. Everywhere else, normally only animals are infected by trypanosomes that, although specific for humans are not pathogenic for them. Yet, in 2004, the first case of human trypanosomiasis was formally identified in India by IRD researcher Philippe Truc, working with the WHO and the Maharashtra State Department of Health (1). The patient was a farmer living in this State who proved to be infected by a trypanosome, T. evansi, usually a parasite of camels and cattle. In South America, North Africa and in a great part of Asia including India, where this parasite is present, many human populations are currently living in contact with infected animals. Scientists from the Universit Libre de Bruxelles , in conjunction with Philippe Truc and Indian medical specialists, under an agreement with WHO (2), carried out analyses on blood serum from the infected patient, which led them to identify the cause of this first case of human trypanosomiasis in India.

Humans possess natural resistance to this parasite, as they have towards related African trypanosomes, like T. brucei. In the latter case, the innate immunity results from the trypanolytic activity of a specific human protein, apolipoprotein L-1 (APOL-1). Once absorbed inside the parasite, this protein forms pores in the parasite's organelle membrane, thus inducing the destruction of the trypanosome. However, the two subspecies T. brucei rhodesiense and T. b. gambiense have, with time, overcome human immune defences by acquiring resistance to APOL-1 and thereby causing sleeping sickness in Africa. In T. b. rhodesiense, this resistance mechanism involves a protein that is peculiar to this subspecies, named SRA (Serum Resistance-associated protein), which interacts strongl
'"/>

Contact: Marie Guillaume-Signoret
fichesactu@paris.ird.fr
33-014-803-7607
Institut de Recherche Pour le Dveloppement
19-Jan-2007


Page: 1 2 3

Related biology news :

1. New, more direct pathways from outside the cell-to-cell nuclei discovered
2. A new brake on cellular energy production discovered
3. New target for HIV/AIDS drugs and vaccine discovered
4. Surprising new species of light-harvesting bacterium discovered in Yellowstone
5. Scratch no more: Gene for itch sensation discovered
6. Fruit fly gene from out of nowhere is discovered
7. A novel molecular dictator with a conscience discovered
8. Gene discovered for type 1 diabetes in children
9. Alzheimers prevention role discovered for prions
10. Link between obesity and enlarged heart discovered by University of Arizona researchers
11. Genetic fellow traveler discovered in Alzheimers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/16/2016)... YORK , Dec. 16, 2016 The global wearable ... USD 12.14 billion by 2021 from USD 5.31 billion in 2016, ... ... is mainly driven by technological advancements in medical devices, launch of ... rising preference for wireless connectivity among healthcare providers, and increasing focus ...
(Date:12/15/2016)... ... has announced the addition of the "Global Military Biometrics Market 2016-2020" ... global military biometrics market to grow at a CAGR of 7.5% during ... on an in-depth market analysis with inputs from industry experts. The report ... The report also includes a discussion of the key vendors operating in ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... MANHASSET, N.Y. , Jan. 17, 2017 /PRNewswire-USNewswire/ ... to speed the advance of precision cancer research. ... State,s largest health care provider, Northwell ... each year. Indivumed, GmbH is a ... individualize anti-cancer medical therapies. Together they will greatly ...
(Date:1/17/2017)... ... January 17, 2017 , ... One ... Technology Consortium™ (SafeTEC™), $3 million in investment towards 15+ TEC Validation Projects™. As ... assays, and their applicability in drug safety assessment, for the industry as a ...
(Date:1/17/2017)... 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... a global Phase 2b induction study in ulcerative ... alpha4beta7 integrin. The aim of this randomized, double-blind, ... safety/tolerability and efficacy of PTG-100 in approximately 240 ... active disease. "We are very ...
(Date:1/16/2017)... 16, 2017   Valentin A. Pavlov, PhD , ... president and CEO of The Feinstein Institute for ... of how the nervous system regulates the immune system, ... bioelectronic medicine devices to treat disease and injury. ... . The paper examines various studies which ...
Breaking Biology Technology:
Cached News: